1832 Asset Management L.P. Increases Stock Position in AbbVie Inc. $ABBV

1832 Asset Management L.P. grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 158.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,590 shares of the company’s stock after purchasing an additional 12,631 shares during the quarter. 1832 Asset Management L.P.’s holdings in AbbVie were worth $3,822,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in ABBV. Norges Bank acquired a new stake in AbbVie during the 2nd quarter worth $4,288,200,000. Nuveen LLC purchased a new stake in shares of AbbVie in the first quarter valued at about $1,819,154,000. Laurel Wealth Advisors LLC boosted its stake in shares of AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after buying an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock worth $804,116,000 after buying an additional 3,666,521 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of ABBV opened at $226.24 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company’s 50 day simple moving average is $228.30 and its 200 day simple moving average is $208.19. The company has a market capitalization of $399.85 billion, a price-to-earnings ratio of 171.39, a PEG ratio of 1.24 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the business earned $3.00 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

Analyst Ratings Changes

Several research firms have recently commented on ABBV. HSBC set a $225.00 price target on AbbVie in a research note on Thursday, October 2nd. Evercore ISI raised their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 30th. Piper Sandler reissued an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.